Galmed To Employ OnKai's Disruptive Artificial Intelligence In Its Planned Phase 2a Clinical Trial In PSC
Portfolio Pulse from Happy Mohamed
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has announced a strategic partnership with OnKai to apply its artificial intelligence (AI) models for enrollment and execution of clinical trials in underserved communities. The collaboration will start with Galmed's Primary Sclerosing Cholangitis (PSC) clinical development program. The clinical development for PSC is expected to start with a Phase 2a study in the fourth quarter of 2023. OnKai's AI platform is anticipated to generate a comprehensive enrollment plan for each trial phase and support the trial in local clinics.
July 10, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Galmed Pharmaceuticals is partnering with OnKai to apply AI in clinical trials, which could potentially speed up the approval process and improve site performance.
The partnership with OnKai allows Galmed to leverage AI in clinical trials, which could potentially streamline the enrollment process, improve site performance, and speed up the approval process. This could positively impact Galmed's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100